ClinicalTrials.gg
CompletedNCT03115996Updated Sep 26, 2018

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers

A Phase 1 interventional study of REGN3918 and Placebo in Healthy Volunteers, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-26.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

To evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses and a multiple dose regimen.

Read the detailed description

Participants will be randomized to single IV or SC or multiple dose treatment with REGN3918 or matched placebo.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

A subject must meet the follow criteria to be eligible for inclusion in the study:

  1. Males and females from 18 to 50 years of age.
  2. Subject is judged to be in good health based on medical history, physical examination, vital sign measurements and laboratory safety tests performed at screening and/or prior to administration of initial dose of study drug
  3. The subject has a less than 30 kg/m2
  4. Willingness to undergo vaccination and antibiotic prophylaxis against N. meningitides.

Key Exclusion Criteria:

A subject who meets any of the following criteria will be excluded from the study:

  1. Any physical examination abnormalities observed during the screening visit.
  2. Hospitalization for any reason within 30 days of the screening visit
  3. Persistent chronic or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals.
  4. Subject has a history of meningococcal infection.
  5. Carriers of Neisseria meningitides based on cultures from naso-pharyngeal swabs during screening.
  6. Subject has had a splenectomy.
  7. Known allergy to penicillin class antibiotics
  8. Known or suspected complement deficiency, or abnormal complement C3, C4 or CH50 during screening.
  9. Recent (within the previous 2 months) bacterial, protozoal, viral or parasite infection requiring systemic treatment.
  10. History of tuberculosis or systemic fungal diseases
  11. infection or HIV seropositivity at the screening visit
  12. Positive , HBcAb, or antibody at the screening visit
  13. History of (except non-melanoma skin cancer or cervical in-situ)
  14. Pregnant or breastfeeding women
  15. Women of and men who are unwilling to practice highly effective prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    REGN3918 (Cohorts 1-4 & 6a)

    Cohorts 1-4 and 6a will receive sequential ascending doses of REGN3918

    Drug: REGN3918

  • Experimental
    Placebo (Cohorts 1-4 & 6a)

    Cohorts 1-4 and 6a will receive placebo

    Drug: Placebo

  • Experimental
    REGN3918 (Cohort 5 & 6b)

    Cohort 5 and 6b will receive multiple doses of REGN3918

    Drug: REGN3918

  • Experimental
    Placebo (Cohort 5 & 6b)

    Cohort 5 and 6b will receive placebo

    Drug: Placebo

Interventions

  • Intravenous (IV) or Subcutaneous (SC)

  • DrugPlacebo

    Matching Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs)

    Time frame: Up to 20 weeks

  2. Severity of TEAEs

    Time frame: Up to 20 weeks

Secondary outcomes

  1. Pharmacokinetic profile of REGN3918; single dose IV and SC

    Assessed via serum concentrations of REGN3918 over time; Area under the Curve (AUC)

    Time frame: Up to 20 weeks

  2. Pharmacokinetic profile of REGN3918; single dose IV and repeated SC doses

    Assessed via serum concentrations of REGN3918 over time; peak concentration Cmax

    Time frame: Up to 20 weeks

  3. Pharmacodynamics profile of REGN3918

    Assessed by CH50 assay over time

    Time frame: Up to 20 weeks

  4. Pharmacokinetic exploratory analysis

    Peak concentration Cmax

    Time frame: Up to 20 weeks

  5. Immunogenicity of REGN3918

    Assessed by measurement of anti-drug antibodies (ADA)

    Time frame: Up to 20 weeks

07

Study locations

1 site
  • Covance Clinical Research Unit (CRU) Ltd.
    Leeds, LS2 9LH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Aug 2018, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2017
First posted
Apr 14, 2017
StartActual
May 10, 2017
Primary completionActual
Aug 31, 2018
CompletionActual
Aug 31, 2018
Last update
Sep 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03115996
Responsible party
Sponsor
First posted
Apr 14, 2017
Start date
May 10, 2017
Primary completion
Aug 31, 2018
Completion
Aug 31, 2018
Last update
Sep 26, 2018

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pozelimab

Start the discussion